gorgevorgian

Stock to buy VRTX: Target +35%

Long
NASDAQ:VRTX   Vertex Pharmaceuticals Incorporated
Vertex stock is still actionable as it rebounds from the 10-week line. It has also blasted back above an alternative entry of 279.23.

The relative strength line has been spiking higher even as VRTX stock and the broader market struggled. The stock has retaken its 50-day moving average, an encouraging sign.

VRTX stock has soared more than 32% higher so far in 2022. This is especially impressive considering the broader market action.

Vertex is also highly profitable. As a result, VRTX stock has an EPS Rating of 99 out of a best-possible 99.

Earnings have grown by an average of 690% over the past three quarters. This easily beats CAN SLIM requirements.

Clause de non-responsabilité

Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.